Smith & Nephew Raises Revenue Growth Outlook After Strong 1H Performance, Sports Medicine and Wound Management Show Strength

Smith & Nephew PLC SNN reported improved revenue, profit, and margin in the first half, progressing towards achieving sustainable higher growth under its 12-point plan.

The medical equipment manufacturing company's 1H revenue rose 5.2% Y/Y (underlying growth of 7.3%) to $2.73 billion, while operating profit climbed to $275 million from $242 million.

Trading profit decreased to $417 million from $440 million. Adjusted EPS slipped to 34.9 cents from 38.1 cents.

For Q2, the company's revenues increased 6.6% (7.8% underlying) to $1.38 billion.

  • Orthopaedics revenue is up 5.8% (4.6% reported), reflecting higher procedure volumes, accelerating robotics adoption, and reducing the China VBP headwind.
  • Sports Medicine & ENT is up 12.0% (10.4% reported), with strong growth across shoulder and knee repair.
  • Advanced Wound Management is up 6.2% (5.5% reported), led by double-digit growth from our negative pressure wound therapy portfolio.

Smith & Nephew, which makes orthopedic implants and prosthetics, wound dressings, and other surgical technologies, also announced that its CFO Anne-Françoise Nesmes will step down during the second quarter of 2024, the board has initiated an external search for a successor.

Guidance: Smith & Nephew increased full-year underlying revenue growth guidance to 6.0%-7.0% (previously 5.0% to 6.0%). 

It left trading profit margin guidance unchanged of at least 17.5%.

Price Action: SNN shares are down 2.84% at $28.47 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!